DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ripretinib
Ripretinib
Ripretinib Demonstrated Activity Across All KIT/PDGFRA Mutations In
Clinical Policy: Sorafenib (Nexavar)
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
2020 Master Class Course Best Practices and Expanding Treatment Options in Soft Tissue Sarcomas Including GIST George D
Rxoutlook® 1St Quarter 2019
Ripretinib Turns Off the Switch in GIST
Standard Oncology Criteria C16154-A
Full Prescribing Information for Surgery and Until Adequate Wound Healing
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
James Patient Education Handouts (A – Z)
November 18 - 21, 2020
(CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Revolutions in Treatment Options in Gastrointestinal Stromal Tumours (Gists): the Latest Updates Revolutions in Treatment Options in GIST
Efficacy and Safety of Ripretinib As ≥4Th-Line Therapy For
Sleep Loss Lethality Is Caused by Gut ROS in Mice and Flies
Malignant, Locally Aggressive Connective Tissue Tumours
Deciphera Pharmaceuticals Address
Part B Drugs Requiring Prior Authorization (Updated May 1, 2021)
Top View
Preferred Drug List 4-Tier Small Group
Oncology Oral, Other Therapeutic Class Review
Medication Prior Authorization Criteria
Drugs with Special Ordering Procedures (SAP Chart)
Prior Authorization Oncology – Nexavar® (Sorafenib Tablets)
Nexavar® (Sorafenib)
Using the Structural Kinome to Systematize Kinase Drug Discovery
Deciphera Pharmaceuticals Address
ATC/DDD Classification (Final)
Clinical Response to Avapritinib by RECIST and Choi Criteria in ≥ 4Th
Therapeutic Advances in Oncology
Premium Value
QINLOCK (Ripretinib) RATIONALE for INCLUSION in PA PROGRAM
Specialty Pipeline MONTHLY UPDATE
AVAPRITINIB (BLU-285) Mpfs 3.7 Mo ORR 20.0% Tkis Currently Approved for Metastatic GIST Disease
Oncology – Qinlock™ (Ripretinib Tablets)
Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
Specialty Pipeline MONTHLY UPDATE
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Virtual Molecular Tumor Board: Recognition and Management of Targetable Tumor Mutations in Less Common Cancer Types
Oncology Medications Policy (1403)
CY 2020 CDER New Molecular Entity (NME) Drug & Original BLA Calendar Year Approvals As of Decemeber 31, 2020
Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
Specialty Pipeline MONTHLY UPDATE
Oncology Agents Policy #: Rx.01.67
SUTTER HEALTH PLUS FORMULARY Drug List for HMO Members – Effective September 1, 2021
CHMP Agenda of the 25-29 January 2021 Meeting
Rozlytrek™ (Entrectinib) (Oral) Document Number: IC-0491 Last Review Date: 07/01/2021 Date of Origin: 09/09/2019 Dates Reviewed: 09/2019, 07/2020, 07/2021
CY 2020 CDER Drug and Biologic Calendar Year Priority Approvals As of December 31, 2020
Ptient-Assistance-And-Reimbursement
Orange Book Cumulative Supplement 7 July 2021
Tyrosine Kinase Inhibitors - Oral
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
Ripretinib—A New Star in the Firmament
Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range Of
Prior Authorization — Premium
Policy Drug(S)
Ripretinib Turns Off the Switch in GIST
Pipeline Report
Gastrointestinal Stromal Tumors (Gists): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
(CHMP) Agenda for the Meeting on 12-15 October 2020
1 Nintedanib Targets KIT D816V Neoplastic Cells Derived
Diarylureas As Antitumor Agents
Clinical Benefit with Ripretinib As ≥Fourth-Line Treatment in Patients
Ripretinib Patients Who Received Ripretinib, So Skin Assessment Is Also Recommended
Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST And
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Update on Molecular Genetics of Gastrointestinal Stromal Tumors
Tropomyosin Receptor Kinase Inhibitors in the Management Of
A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity
Tyrosine Kinase Receptors in Oncology
1 Nintedanib Targets KIT D816V Neoplastic Cells Derived From